Form 4: Monopar CEO Chandler Robinson's Stock Transactions

Monopar Therapeutics CEO Chandler Robinson reported the acquisition of 8,724 common shares through RSU vesting and the disposition of 2,558 shares for tax withholding.

Summary

• Chandler Robinson, Chief Executive Officer and Director of Monopar Therapeutics, reported transactions involving the company's common stock.
• On December 31, 2025, 8,724 shares of common stock were acquired through the vesting and settlement of restricted stock units (RSUs).
• Concurrently, 2,558 shares were disposed of at a price of $65.3 per share to cover applicable withholding taxes related to the RSU vesting.
• Following these transactions, Robinson directly beneficially owns 85,718 shares of common stock.
• Additionally, Robinson indirectly beneficially owns 272,026 shares through Tactic Pharma LLC, disclaiming beneficial ownership except for his pecuniary interest therein.
• The filing details several RSU grants: 31,905 units on February 2, 2022 (vesting until December 31, 2025), 33,803 units on February 1, 2023 (vesting until December 31, 2026), and 79,899 units on March 4, 2025 (6,002 vested immediately, remaining vesting until December 31, 2028).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transactions are routine RSU vesting and tax withholding, which are expected. The vesting of shares increases the CEO's direct ownership, aligning interests with shareholders, which is a positive. No significant negative implications are present.

Positives

• The acquisition of 8,724 shares through RSU vesting demonstrates continued equity alignment between the CEO and shareholders.
• The long-term vesting schedules for various RSU grants, extending to December 31, 2028, indicate a sustained commitment of the CEO to the company's future performance.

Negatives

• The disposition of 2,558 shares was solely for tax withholding purposes, which is a standard practice upon RSU vesting and not indicative of a negative outlook.

Risks

• Dr. Robinson disclaims beneficial ownership of the 272,026 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein, which could imply limited direct control or influence over these shares.

Future Outlook

The future outlook, as indicated by the RSU vesting schedules, shows a continued equity incentive structure for the CEO extending through December 31, 2028, aligning management's interests with long-term shareholder value creation.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, specifically related to equity compensation. It does not provide information on broader industry trends or competitive landscape, but rather details how a key executive's ownership stake is evolving through pre-scheduled vesting events.

Related Party Transactions

• Chandler Robinson, as a manager of Tactic Pharma LLC, may be deemed to share voting and dispositive power over 272,026 shares held by Tactic Pharma LLC. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The transactions demonstrate the CEO's continued equity alignment with the company's performance through RSU vesting, which can be viewed positively as it ties executive compensation to shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Continued vesting of restricted stock units for Chandler Robinson on a quarterly basis until December 31, 2028, as per the various grant schedules.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to RSU vesting and tax withholding. Such transactions are pre-scheduled and do not typically reflect a change in the company's fundamental outlook or the insider's sentiment beyond the existing compensation structure. Therefore, it does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate based solely on this filing.

Keywords

Monopar Therapeutics, MNPR, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, Chandler Robinson, CEO, Stock Vesting, Beneficial Ownership